{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:37:14Z","timestamp":1782301034399,"version":"3.54.5"},"reference-count":68,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100014471","name":"Mundipharma Research Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mycoses"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Invasive candidiasis (IC), life\u2010threatening fungal infections with high economic burden, are often treated first\u2010line with daily intravenous echinocandins. A new once weekly echinocandin, rezafungin, demonstrated statistically non\u2010inferior efficacy and numerically shorter intensive care unit (ICU) stay compared to caspofungin in clinical trials, offering potential for earlier discharge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the cost\u2010effectiveness of rezafungin versus daily echinocandins for the treatment of IC from a UK healthcare perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An economic model was developed including a short\u2010term decision tree (treatment duration \u2264\u200930\u2009days) and a long\u2010term Markov model (for lifetime outcomes). Considering the impact IC has on a patient's life expectancy and quality of life, a cost\u2010utility analysis was performed. A cost\u2010minimisation analysis assuming similar efficacy among echinocandins was included as scenario analysis. Treatment response was assessed at days 5\/14 with nonresponders switching to second\u2010line treatment. Patients with negative repeat blood cultures could step down to oral fluconazole. Rezafungin's weekly administration was estimated to lead to early discharge for 16% of patients. Risk of death was included. Efficacy and resource use estimates were from pooled trial data. Unit costs, utilities, long\u2010term mortality were from published literature and UK databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Rezafungin was estimated to be cost\u2010saving compared to daily echinocandins (discounted incremental costs: \u2212\u00a36028 to \u2212\u00a36727 vs. daily echinocandins). Quality\u2010adjusted life\u2010years (QALYs) were similar (incremental QALY: 0.03 vs. daily echinocandins), resulting in rezafungin being cost\u2010effective. Results were most sensitive to varying mortality and ICU length of stay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Once weekly rezafungin is a cost\u2010saving and cost\u2010effective treatment option in IC from the UK healthcare perspective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/myc.70148","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:46:03Z","timestamp":1770882363000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost\u2010Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom"],"prefix":"10.1111","volume":"69","author":[{"given":"Noemi","family":"Muszbek","sequence":"first","affiliation":[{"name":"Visible Analytics  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0515-7632","authenticated-orcid":false,"given":"Alisha","family":"Angdembe","sequence":"additional","affiliation":[{"name":"Visible Analytics  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Garcia\u2010Vidal","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednic de Barcelona  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Bielicka","sequence":"additional","affiliation":[{"name":"Mundipharma Research Ltd  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Abrams","sequence":"additional","affiliation":[{"name":"Visible Analytics  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Tolley","sequence":"additional","affiliation":[{"name":"Tolley Health Economics Ltd  Buxton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ruhnke","sequence":"additional","affiliation":[{"name":"Helios Klinikum Aue  Aue\u2010Bad Schlema Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Lebmeier","sequence":"additional","affiliation":[{"name":"Athena Market Access Solutions Ltd  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Visible Analytics  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Manamley","sequence":"additional","affiliation":[{"name":"Mundipharma Research Ltd  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Dickerson","sequence":"additional","affiliation":[{"name":"Mundipharma Research Ltd  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.26"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1315399"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jof3040057"},{"key":"e_1_2_10_5_1","unstructured":"World Health Organization \u201cWHO Fungal Priority Pathogens List to Guide Research Development and Public Health Action \u201dGeneva (2022)."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-019-2497-3"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","unstructured":"A. H. P.Soriano P.Puerta\u2010Alcalde C.Garcia\u2010Vidal A.Pagotto D.Goncalves\u2010Bradley andP. E.Verweij \u201cInvasive Candidiasis: Current Clinical Challenges and Unmet Needs in Adult Populations \u201d(2023).","DOI":"10.1093\/jac\/dkad139"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2019.04.024"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2019.07.002"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1944-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4811-1"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1054\/drup.1998.0059"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ933"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05599-w"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12039"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.ss6808a1"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2003.39.10.799473"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00872-6"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00776-4"},{"key":"e_1_2_10_20_1","unstructured":"European Medicines Agency \u201cEU\/3\/20\/2385: Orphan Designation for the Treatment of Invasive Candidiasis \u201d(2021)."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1380"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02324-8"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00551-0"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.599"},{"key":"e_1_2_10_25_1","unstructured":"A.Soriano S.Dickerson A.Das T.Sandison andG.Thompson \u201cEarly Outcomes and Intensive Care Unit Length of Stay With Rezafungin Once\u2011Weekly Echinocandin in Invasive Candid Disease \u201dSymposium on Intensive Care & Emergency Medicine 2021."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-024-05152-2"},{"key":"e_1_2_10_27_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cNICE Health Technology Evaluations: The Manual \u201d(2022)."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.10.221"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106614"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13290"},{"key":"e_1_2_10_31_1","unstructured":"All Wales Medicines Strategy Group \u201cForm B Guidance Notes \u201d(2023)."},{"key":"e_1_2_10_32_1","unstructured":"Scottish Medicines Consortium \u201cWorking With SMC \u2013 A Guide for Manufacturers \u201d(2023)."},{"key":"e_1_2_10_33_1","unstructured":"\u201cNational Life Tables: UK \u201d(2021) https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables."},{"key":"e_1_2_10_34_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cCHTE Method Review: Discounting \u201d(2020)."},{"key":"e_1_2_10_35_1","unstructured":"Scottish Medicines Consortium \u201cGuidance to Submitting Companies for Completion of New Product Assessment Form (NPAF) \u201d(2022)."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2573-8"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2013.05.004"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1638789"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-3147-9"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1143-1"},{"key":"e_1_2_10_41_1","unstructured":"Mundipharma \u201cIntegrated Safety Analysis \u201d(2023)."},{"key":"e_1_2_10_42_1","unstructured":"\u201cDrugs and Pharmaceutical Electronic Market Information Tool (eMIT) \u201d(2023) https:\/\/www.gov.uk\/government\/publications\/drugs\u2010and\u2010pharmaceutical\u2010electronic\u2010market\u2010information\u2010emit."},{"key":"e_1_2_10_43_1","unstructured":"\u201cBritish National Formulary (BNF) \u201d(2023) https:\/\/bnf.nice.org.uk\/."},{"key":"e_1_2_10_44_1","unstructured":"Wockhardt UK Ltd \u201cAnidulafungin 100 mg Powder for Concentrate for Solution for Infusion 2022 \u201dhttps:\/\/www.medicines.org.uk\/emc\/product\/13906\/smpc#gref."},{"key":"e_1_2_10_45_1","unstructured":"Sun Pharmaceutical Company \u201cFluconazole 150 mg Capsules: SmPC 2021 \u201dhttps:\/\/www.medicines.org.uk\/emc\/product\/4720\/smpc#gref."},{"key":"e_1_2_10_46_1","unstructured":"Flynn Pharma Ltd \u201cCaspofungin 70 mg Powder for Concentrate for Solution for Infusion SmPC 2022 \u201dhttps:\/\/www.medicines.org.uk\/emc\/product\/8956\/smpc#gref."},{"key":"e_1_2_10_47_1","unstructured":"Astellas Pharma Ltd \u201cMycamine 50 mg Powder for Concentrate for Solution for Infusion SmPC 2023 \u201dhttps:\/\/www.medicines.org.uk\/emc\/product\/6315\/smpc#gref."},{"key":"e_1_2_10_48_1","unstructured":"ADVANZ Pharma \u201cFluconazole 2 mg\/ml Solution for Infusion 2021 \u201dhttps:\/\/www.medicines.org.uk\/emc\/product\/3378\/smpc#gref."},{"key":"e_1_2_10_49_1","unstructured":"Joint Formulary Committee \u201cBritish National Formulary (BNF): Amphotericin B 2023\u201d."},{"key":"e_1_2_10_50_1","unstructured":"Napp Pharmaceuticals Limited \u201cRezzayo 200 mg Powder for Concentrate for Solution for Infusion 2024 \u201dhttps:\/\/www.medicines.org.uk\/emc\/product\/15479\/smpc#gref."},{"key":"e_1_2_10_51_1","unstructured":"Lord Carter of Coles \u201cTransforming NHS Pharmacy Aseptic Services in England \u201dDepartment of Health and Social Care (2020)."},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad239"},{"key":"e_1_2_10_53_1","unstructured":"Mundipharma \u201cClinical Study Report: A Phase 2 Multicenter Randomized Double\u2010Blind Study of the Safety Tolerability and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step\u2010Down in the Treatment of Subjects With Candidemia and\/or Invasive Candidiasis \u201d2020."},{"key":"e_1_2_10_54_1","unstructured":"K.Jones C.Weatherly H.Birch et\u00a0al. \u201cUnit Costs of Health and Social Care 2022 Manual \u201dKent: Personal Social Services Research Unit (University of Kent) & Centre for Health Economics (University of York) (2023)."},{"key":"e_1_2_10_55_1","unstructured":"National Institute for Health R \u201cInteractive Costing Tool Tariff Data 2023\u20132024 \u201dhttps:\/\/www.nihr.ac.uk\/documents\/guidance\u2010using\u2010the\u2010interactive\u2010costing\u2010tool\u2010ict\/12170."},{"key":"e_1_2_10_56_1","unstructured":"National Schedule of NHS Costs \u201c2021\/22 \u201d(2023) https:\/\/www.england.nhs.uk\/publication\/2021\u201022\u2010national\u2010cost\u2010collection\u2010data\u2010publication\/."},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.03.016"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.839948"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1417312"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2003.08.009"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac545"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.10.029"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0171131"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004251"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05854-8"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X11401031"},{"key":"e_1_2_10_67_1","unstructured":"\u201cCancer Quality of Life Survey \u201d(2023) https:\/\/www.cancerdata.nhs.uk\/cancerqol."},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00004"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903072565"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.70148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/myc.70148","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/myc.70148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:14:13Z","timestamp":1773220453000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/myc.70148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/myc.70148"],"URL":"https:\/\/doi.org\/10.1111\/myc.70148","archive":["Portico"],"relation":{},"ISSN":["0933-7407","1439-0507"],"issn-type":[{"value":"0933-7407","type":"print"},{"value":"1439-0507","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"2025-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70148"}}